Kimer Med

Executive Summary

Kimer Med is a New Zealand-based preclinical biotechnology company focused on developing novel immunotherapies and targeted treatments for cancer and autoimmune diseases. Founded in 2018, the company has raised $14 million to advance its pipeline of immunomodulatory candidates. Kimer Med's proprietary platform aims to harness the immune system to selectively eliminate cancer cells while sparing healthy tissue, and to rebalance immune responses in autoimmune conditions. The company is currently in the preclinical stage, with lead programs targeting solid tumors and inflammatory diseases. Kimer Med's approach leverages deep insights into immunology and tumor biology, positioning it as an emerging player in the oncology and immunology space.

Upcoming Catalysts (preview)

• Q3 2026Completion of lead candidate IND-enabling studies50% success
• Q4 2026Presentation of preclinical efficacy data at a major conference60% success
• Q1 2027Announcement of a strategic partnership or licensing deal30% success